Table 2.
The adjusted ORs (95% CIs) for the association between the quartiles of urinary PAHs and OAB, NHANES 2005–2016
| Nocturia score | Urgenturia score | OBASS LEVEL | OAB+ | |
|---|---|---|---|---|
| 1-Hydroxynaphthalene, ng/L | ||||
| Q1 | Reference | Reference | Reference | Reference |
| Q2 | 1.11 (0.91, 1.35) | 1.30 (1.04, 1.63)# | 1.17 (0.97, 1.43) | 1.22 (0.92, 1.65) |
| Q3 | 1.09 (0.92, 1.31) | 1.36 (1.02, 1.80)# | 1.18 (0.80, 1.45) | 1.22 (0.89, 1.68) |
| Q4 | 1.22 (1.01, 1.46)# | 1.93 (1.47, 2.51)## | 1.34 (1.09, 1.65)## | 1.74 (1.30, 2.32)## |
| p for trend | 0.041# | 0.001## | 0.007## | 0.001## |
| 2-Hydroxynaphthalene, ng/L | ||||
| Q1 | Reference | Reference | Reference | Reference |
| Q2 | 1.12 (0.94, 1.31) | 1.22 (0.95, 1.55) | 1.15 (1.01, 1.34) | 1.21 (0.94, 1.55) |
| Q3 | 1.16 (0.98, 1.38) | 1.25 (0.95, 1.65) | 1.20 (1.01, 1.43)# | 1.43 (1.10, 1.85)## |
| Q4 | 1.39 (1.13, 1.70)## | 1.57 (1.16, 2.14)## | 1.40 (1.14, 1.73)## | 1.73 (1.28, 2.34)## |
| p for trend | 0.003## | 0.008## | 0.003## | 0.001## |
| 3-Hydroxyfluorene, ng/L | ||||
| Q1 | Reference | Reference | Reference | Reference |
| Q2 | 1.01 (0.84, 1.22) | 1.02 (0.79, 1.32) | 1.08 (0.89, 1.32) | 0.93 (0.71, 1.22) |
| Q3 | 0.90 (0.74, 1.08) | 1.05 (0.82, 1.35) | 0.99 (0.82, 1.19) | 0.83 (0.64, 1.08) |
| Q4 | 1.08 (0.89, 1.31) | 1.62 (0.81, 2.12)## | 1.21 (0.99, 1.49) | 1.43 (1.05, 1.95)# |
| p for trend | 0.722 | 0.001## | 0.129 | 0.036# |
| 2-Hydroxyfluorene, ng/L | ||||
| Q1 | Reference | Reference | Reference | Reference |
| Q2 | 1.14 (0.95, 1.36) | 1.18 (0.91, 1.54) | 1.22 (1.00, 1.48)# | 1.02 (0.75, 1.40) |
| Q3 | 1.22 (0.98, 1.48)# | 1.11 (0.85, 1.42) | 1.27 (1.04, 1.55)# | 1.17 (0.88, 1.54) |
| Q4 | 1.28 (1.05, 1.55)# | 1.70 (1.27, 2.27)## | 1.42 (1.19, 1.75)## | 1.41 (1.00, 1.99)# |
| p for trend | 0.011# | 0.001## | 0.002## | 0.026# |
| 1-Hydroxyphenanthrene, ng/L | ||||
| Q1 | Reference | Reference | Reference | Reference |
| Q2 | 1.15 (0.97, 1.35) | 1.07 (0.85, 1.36) | 1.21 (1.01, 1.43)# | 1.12 (0.84, 1.49) |
| Q3 | 1.27 (1.05, 1.54)# | 1.28 (0.99, 1.67) | 1.34 (1.09, 1.63)## | 1.36 (1.00, 1.85)# |
| Q4 | 1.23 (1.04, 1.46)# | 1.34 (1.03, 1.72)# | 1.32 (1.13, 1.57)## | 1.30 (0.96, 1.76) |
| p for trend | 0.022## | 0.021# | 0.002## | 0.053 |
| 1-Hydroxypyrene, ng/L | ||||
| Q1 | Reference | Reference | Reference | Reference |
| Q2 | 1.09 (0.91, 1.31) | 1.16 (0.90, 1.51) | 1.20 (0.99, 1.43) | 1.21 (0.91, 1.62) |
| Q3 | 1.20 (1.02, 1.39)# | 1.45 (1.13, 1.86)## | 1.34 (1.15, 1.58)## | 1.47 (1.11, 1.94)## |
| Q4 | 1.19 (1.02, 1.38)## | 1.63 (1.23, 2.14)## | 1.31 (1.13, 1.52)## | 1.39 (1.02, 1.91)# |
| p for trend | 0.003# | 0.001## | 0.001## | 0.018# |
ORs were adjusted for all covariates including age, logarithmic urinary (mg/dL), gender, race, body mass index (BMI), educational level, marriage, poverty income ratio, diabetes, hypertension, and metabolic syndrome.
OAB+, participants had overactive bladder; CI, confidence interval.
# p < 0.05.
## p < 0.01.